Response determination criteria for ELISPOT: Toward a standard that can be applied across laboratories

Methods in Molecular Biology

Volumn 792, Issue , 2012, Pages 185-196

  Moodie, Zoe ^a   Price, Leah ^b   Janetzki, Sylvia ^c   Britten, Cedrik M ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ZellNet Consulting Inc   (United States)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

ELISPOT assay; Harmonization; Positive response criteria; Replicate variation; Statistical hypothesis test

Indexed keywords

ARTICLE; CD8+ T LYMPHOCYTE; CYTOLOGY; DIAGNOSTIC PROCEDURES; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNOLOGY; LABORATORY; MONONUCLEAR CELL; NONPARAMETRIC TEST; STANDARD;

CD8-POSITIVE T-LYMPHOCYTES; CLINICAL LABORATORY TECHNIQUES; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; LABORATORIES; LEUKOCYTES, MONONUCLEAR; STATISTICS, NONPARAMETRIC;

EID: 80555129210     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-325-7_15     Document Type: Article

References (24)

1. Czerkinsky, C., Andersson, G., Ekre, H.P., Nilsson, L.A., Klareskog, L., and Ouchterlony, O. (1988) Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 110:29-36
2. Herr, W., Schneider, J., Lohse, A.W., Meyer zum Buschenfelde, K., and Wolfel, T. (1996) Detection and quantification of blood-derived CD8+T lymphocytes secreting tumor necrosis factor a in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 191:131-142 (Pubitemid 26173515)
3. Herr, W., Protzer, U., Lohse, A.W., Gerken, G., Meyer zum Buschenfelde, K.H., and Wolfel, T. (1998) Quantification of CD8+T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J Infect Dis 178:260-265 (Pubitemid 28328104)
4. Smith, S.G., Joosten. S.A., Verscheure, V., Pathan, A.A., McShane, H., Ottenhoff, T.H., et al. (2009) Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS ONE 4(11): e7972. doi:10.1371/journal.pone.0007972
5. Schloot, N.C., Meierhoff, G., Karlsson, F.M., Ott, P., Putnam, A.,and Lehmann, P., et al. (2003) Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun 21:365-376 (Pubitemid 37414931)
6. Asai, T., Storkus, W.J. and Whiteside, T.L. (2000) Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol 7:145-154 (Pubitemid 30132104)
7. Cox, J.H., Ferrari, G., and Janetzki, S. (2006) Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods 38:274-282
8. Speiser, D.E., Pittet, M.J., Guillaume, P., Lubenow, N., Hoffman, E., Cerottini, J.C., et al. (2004) Ex vivo analysis of human antigen-specific CD8+T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother 27:298-308 (Pubitemid 38833326)
9. Scheibenbogen, C., Romero, P., Rivoltini, L., Herr, W., Schmittel, A., Cerottini, J.C., et al. (2000) Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 20;244: 81-89
10. Janetzki, S., Panageas, K.S., Ben-Porat, L., Boyer, J., Britten, C.M., Clay, T.M., et al. (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57:303-315 (Pubitemid 350295382)
11. Britten, C.M., Gouttefangeas, C., Welters, M.J., Pawelec, G., Koch, S., Ottensmeier, C., et al. (2008) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57:289-302 (Pubitemid 350295380)
12. Cox, J.H., Ferrari, G., Kalams, S.A., Lopaczynski, W., Oden, N., and D'Souza, M.P. (2005) Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 21:68-81 (Pubitemid 40179803)
13. Janetzki, S., Britten, C.M., Kalos, M., Levitsky, H.I., Maecker, H.T., Melief, C.J., et al. (2009) "MIATA"-minimal information about T cell assays. Immunity 31:527-528
14. Smith, J.G., Joseph, H.R., Green, T., Field, J.A., Wooters, M., Kaufhold, R.M., et al (2007) Establishing acceptance criteria for cellmediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol 14(5):527-37
15. Janetzki, S., Cox, J.H., Oden, N., Ferrari, G. (2005) Standardization and validation issues of the ELISPOT assay. Methods Mol Biol 302:51-86
16. Janetzki, S., Schaed, S., Blachere, N.E., Ben-Porat, L., Houghton, A.N., Panageas, K.S. (2004) Evaluation of Elispot assays: influence of method and operator on variability of results. J Immunol Methods 291(1-2): 175-83 (Pubitemid 39164347)
17. Ryan, J.E., Ovsyannikova, I.G., Dhiman, N., Pinsky, N.A., Vierkant, R.A., Jacobson, R.M., et al. (2005) Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma-secreting T cells. Scand J Clin Lab Invest 65(8):681-9 (Pubitemid 41759164)
18. Cox, J.H., Ferrari, G., Kalams, S.A., Lopaczynski, W., Oden, N. and D'Souza, M.P. (2005) Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 21(1):68-81 (Pubitemid 40179803)
19. Moodie, Z., Price, L., Gouttefangeas, C., Mander, A., Janetzki, S., Lower, M., et al. (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 59(10):1489-501
20. Dubey, S., Clair, J., Fu, T.M., Guan, L., Long, R., Mogg, R., et al. (2007) Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzymelinked immunospot assay. J Acquir Immune Defic Syndr 45:20-27 (Pubitemid 46684439)
21. Hudgens, M.G., Self, S.G., Chiu, Y.L., Russell, N.D., Horton, H. and McElrath, M.J. (2004) Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J Immunol Methods 288:19-34 (Pubitemid 38739249)
22. Moodie, Z., Huang, Y., Gu, L., Hural, J. and Self, S.G. (2006) Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 315:121-132 (Pubitemid 44419512)
23. Herr, W., Linn, B., Leister, N., Wandel, E., Meyer zum Buschenfelde, K., and Wolfel, T. (1997) The use of computer-assisted video image analysis for the quantification of CD8+T lymphocytes producing tumor necrosis factor spots in response to peptide antigens. J Immunol Methods 203:141-152 (Pubitemid 27179612)
24. Westfall, P.H. and Young, S.S. (1993) Resampling-based multiple testing: examples and methods for p-value adjustment. John Wiley and Sons, New York